ArticleCancers2025

The Efficacy of First-Line Pembrolizumab Monotherapy in Patients with Metastatic NSCLC Aged ≥70 Years with High PD-L1 (TPS ≥ 50%) Expression: A Multicenter Real-World Study.

Filip Marković et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.